Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
421 Leser
Artikel bewerten:
(1)

Berman Tabacco Announces Client Recovery in $6.5 Million Self-Litigated False Claims Act Settlement Involving Eight Former Executives and Employees of Aegerion Pharmaceuticals, Inc.

BOSTON, MA / ACCESSWIRE / December 20, 2019 / Berman Tabacco announces a $6.5 million settlement in a False Claims Act case brought against eight former executives and employees of Aegerion Pharmaceuticals, Inc. ("Aegerion" or the "Company") by three former employees. The current settlement resolves claims alleging that defendants defrauded Medicare by causing the submission of payment claims for the prescription drug Juxtapid after promoting it for unapproved uses. The Company previously reached a civil false claims settlement with the United States and certain individual states for $28.8 million and agreed to pay a criminal fine and forfeiture of $7.2 million, bringing the total recovery to the United States and certain individual states in this matter to $42.5 million.

The three whistleblowers or "Relators" were former sales representatives at Aegerion, each with decades of experience in the pharmaceutical, biotech, and health care industries. They were each drawn to Aegerion by the promise of helping patients with a rare genetic disorder obtain potentially life-saving drug therapy.

Juxtapid is an orphan drug approved by the FDA to treat patients with homozygous familial hypercholesterolemia ("HoFH"), an extremely rare genetic disorder with low life expectancy. In July 2013, shortly after the FDA approved Juxtapid, the whistleblowers brought their action alleging that the defendants aggressively promoted and distributed Juxtapid by targeting patients who did not suffer from HoFH. For example, the whistleblowers alleged that Aegerion made false and misleading statements to doctors in order to have them prescribe Juxtapid more widely, notwithstanding the FDA's efficacy and safety concerns that had prompted it to limit Juxtapid's use to the treatment of HoFH.

In 2017, the United States intervened in the whistleblowers' action for purposes of settling claims with Aegerion under an arrangement where Aegerion agreed to plead guilty to two misdemeanor charges. The United States declined to intervene in the whistleblowers' claims against Aegerion's senior management and other individual defendants. Since 2017, whistleblowers have self-litigated the action against these individuals and defeated multiple motions to dismiss the case. Following a mediation, the parties agreed to a settlement whereby defendants collectively will pay $6.5 million to the United States, of which the whistleblowers will share approximately $1,787,500. Defendants deny liability.

"This settlement draws to an end six years of litigation and represents a significant recovery for the United States," commented Berman Tabacco partner Patrick Egan, lead attorney on the case. "By self-litigating against the senior executives at Aegerion, the whistleblowers demonstrated their commitment and courage to take on the alleged architects of the scheme."

"We are very proud of our clients. Not only did they alert the government to what they witnessed firsthand, but they continued to fight on even after Aegerion had settled," commented Rory Delaney, one of whistleblowers' counsel from the outset.

The whistleblowers are represented by the attorneys of Berman Tabacco's Boston office, including Patrick T. Egan, Bryan A. Wood, Stephen Ryan, Jr., and Nicole Maruzzi, alongside attorneys from Delaney Kester LLP, including Royston H. Delaney and Ilyas J. Rona of Boston, Massachusetts; and Charles F. Kester of Los Angeles, California.

Berman Tabacco is a national law firm representing whistleblowers nationwide in actions filed under the False Claims Act, as well as before the SEC, CFTC, IRS and state regulators in connection with their enforcement of federal and state laws. The firm also represents institutions and individuals in lawsuits seeking to recoup losses caused by corporate board misconduct and violations of securities and antitrust laws. The firm has 37 lawyers in Boston, Massachusetts and San Francisco, California. This notice may constitute attorney advertising.

Contact:

Patrick T. Egan
pegan@bermantabacco.com
(617) 542-8300

SOURCE: Berman Tabacco



View source version on accesswire.com:
https://www.accesswire.com/570968/Berman-Tabacco-Announces-Client-Recovery-in-65-Million-Self-Litigated-False-Claims-Act-Settlement-Involving-Eight-Former-Executives-and-Employees-of-Aegerion-Pharmaceuticals-Inc

© 2019 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.